Revolution Medicines is a global, commercial-state oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers. Leveraging its differentiated RAS(ON) tri-complex inhibitor platform, the company is advancing a broad, integrated portfolio of oral RAS(ON) inhibitors designed to directly target the active, cancer-driving state of RAS. Founded on rigorous scientific inquiry and a willingness to challenge long-held assumptions, Revolution Medicines is committed to changing the trajectory of disease for patients with RAS-addicted cancers worldwide.

Our people are united by a shared way of working: follow the science, challenge assumptions, act with urgency and hold ourselves to a high standard of rigor—all in service of patients.

The Opportunity

As a Vice President reporting to the SVP of Translational Research in Biology, the individual will collaborate with colleagues in Research and Development to serve as the scientific and organizational leader of the Cancer Pharmacology function and help shape the translational research strategy supporting Revolution Medicines' discovery and development portfolio. The cancer pharmacology effort is accountable for delivering mechanistic, efficacy, PK/PD, and combination strategy insights that enable candidate selection, IND-enabling studies, translational biomarker strategies, and clinical development decisions. The candidate will serve as a key scientific leader in disease area strategy discussions, helping prioritize indications, combination opportunities, biomarker hypotheses, and portfolio investments. Functional responsibilities include leadership, mentoring and development of a productive cancer pharmacology group, a facile translational research operations group, and AI/ML integration for modern data infrastructure and analytics. The leader is expected to work cross-functionally across a broad and growing R&D organization, including functions driving ADME, safety, regulatory affairs, and clinical development. We are seeking an experienced and visionary leader with strong interpersonal skills and an ability to lead a strong and diverse translational research team. The ideal candidate will:

Define and implement forward translation strategies for RAS-driven diseases supervising an internal team of highly experienced and accomplished cancer pharmacologists to drive in vivo pharmacology in parallel with scientific discovery and combination strategies.

Drive efforts to organize and harmonize large data sets across the organization, as part of a digital data transformation initiative, and accelerate integration and analysis of large scale preclinical and clinical datasets into our translational research strategy.

Champion the integration of advanced computational approaches, AI/ML methodologies, and modern data infrastructure to enable data-driven decision making across discovery, translational research, and development.

Be accountable for a sophisticated core operations group that can meet diverse needs across research, including international preclinical CRO management and internal regulatory and operational interactions.

Leverage strong cross-functional skills to develop productive collaborations with diverse groups across the organization including research, development, and project teams.

Engage with external collaborations including academic centers, CROs, non-profit organizations and experts to drive execution of key projects and bring in new technologies.

Represent Revolution Medicines externally through scientific publications, conference presentations, advisory boards, and strategic collaborations.

Be a strategic leader and thought partner for disease area strategy initiatives to accelerate our pipeline, stay up to date with industry trends to identify future translational gaps and opportunities, develop plans to implement and help programs pivot to ensure future success.

Required Skills, Experience, and Education

PhD in oncology, pharmacology, cancer biology, molecular biology, or related discipline, and background in the principles of oncology.